Publications by authors named "C Maccalli"
Gut microbiota regulates various aspects of human physiology by producing metabolites, metabolizing enzymes, and toxins. Many studies have linked microbiota with human health and altered microbiome configurations with the occurrence of several diseases, including cancer. Accumulating evidence suggests that the microbiome can influence the initiation and progression of several cancers.
View Article and Find Full Text PDFArticle Synopsis
- - COST (European Cooperation in Science and Technology) funds and coordinates scientific research in Europe, recently supporting the "Genome Editing to treat Human Diseases" (GenE-HumDi) network that connects various stakeholders including pharmaceutical companies and academia.
- - GenE-HumDi’s main goal is to fast-track the use of genome editing for treating human diseases through organized working groups that improve technologies, assess safety, and create regulatory guidelines.
- - The initiative aims to standardize practices, share knowledge, and effectively communicate the potential of genome editing to the public, highlighted by their first meeting in March 2023 in Granada, Spain.
The poor efficacy of chimeric antigen receptor T-cell therapy (CAR T) for solid tumors is due to insufficient CAR T cell tumor infiltration, in vivo expansion, persistence, and effector function, as well as exhaustion, intrinsic target antigen heterogeneity or antigen loss of target cancer cells, and immunosuppressive tumor microenvironment (TME). Here we describe a broadly applicable nongenetic approach that simultaneously addresses the multiple challenges of CAR T as a therapy for solid tumors. The approach reprograms CAR T cells by exposing them to stressed target cancer cells which have been exposed to the cell stress inducer disulfiram (DSF) and copper (Cu)(DSF/Cu) plus ionizing irradiation (IR).
View Article and Find Full Text PDFArticle Synopsis
- Gliomas are tough brain tumors that are hard to treat because of where they grow and how they resist regular therapies.
- Over the last 20 years, more people have been getting gliomas, and scientists are looking at small molecules called microRNAs (miRNAs) to help fight them.
- These miRNAs are tricky because they can mess with important genes and proteins that help control tumor growth, so it's super important to find out which miRNAs to target for better treatment.
Background: The mechanism of tumor immune escape and progression in colorectal cancer (CRC) is widely investigated in-vitro to help understand and identify agents that might play a crucial role in response to treatment and improve the overall survival of CRC patients. Several mechanisms of immune escape and tumor progression, including expression of stemness markers, inactivation of immunoregulatory genes by methylation, and epigenetic silencing, have been reported in CRC, indicating the potential of demethylating agents as anti-cancer drugs. Of these, a chemotherapeutic demethylating agent, Decitabine (DAC), has been reported to induce a dual effect on both DNA demethylation and histone changes leading to an increased expression of target biomarkers, thus making it an attractive anti-tumorigenic drug.
View Article and Find Full Text PDF